KIN-102 / Kinimmune - LARVOL DELTA

Kinimmune wins highly competitive NCI funding to advance solid tumor immunotherapy for patients refractory to checkpoint inhibitors (Businesswire) - "Kinimmune, Inc...announced that the company has received $400k in funding from the National Cancer Institute (NCI) at the National Institutes of Health for its Phase I STTR application, 'Development of a tumor-retentive immunostimulant as adjunct therapy for solid tumor cancers'. This award will advance the preclinical development of KIN-102, an immunostimulant for intratumoral injection that is designed to turn ‘cold’ tumors ‘hot’ for synergy with immuno-oncology drugs such as checkpoint inhibitors."

Financing • Oncology • Solid Tumor